Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study.
No abstract available
COI Statement
Competing interests: The authors declare no competing interests.
References:
Elsallab M, Ellithi M, Lunning MA, D’Angelo C, Ma J, Perales MA, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143:2099–105.
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984–9.
Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390:2047–60.
Accorsi Buttini E, Farina M, Lorenzi L, Polverelli N, Radici V, Morello E, et al. High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: a case report and literature review. Front Oncol. 2023;13. 10.3389/FONC.2023.1036455.
Galli E, Frioni F, Malara T, Attardi E, Bellesi S, Hohaus S, et al. FLT3 mutated acute myeloid leukemia after CD19 CAR-T cells. Mediterr J Hematol Infect Dis. 2024;16. 10.4084/MJHID.2024.029.